Cytarabine liposome injection is a sustained-release formulation of the active ingredient cytarabine designed for direct administration into the cerebrospinal fluid (CSF). Cytarabine is a cell cycle phase-specific antineoplastic agent, affecting cells only during the S-phase of cell division. Intracellularly, cytarabine is converted into cytarabine-5′-triphosphate (ara-CTP), which is the active metabolite. The mechanism of action is not completely understood, but it appears that ara-CTP acts primarily through inhibition of DNA polymerase. Incorporation into DNA and RNA may also contribute to cytarabine cytotoxicity. Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.

Use in Cancer

Cytarabine is approved to be used with other drugs to treat:

• Acute non-lymphocytic leukemia in adults and children.

Cytarabine is also approved to prevent and treat:

• Meningeal leukemia (leukemia that has spread to the meninges). It is given as intrathecal therapy.

Cytarabine may also be used to treat:

• Acute lymphoblastic leukemia (ALL).
• Chronic myelogenous leukemia (CML) in the blastic phase.

Cytarabine is also being studied in the treatment of other types of cancer.

Cytarabine is also available in a different form, combined with Daunorubicin Hydrochloride

Contraindications

• Cytarabine is contraindicated in patients who have had a hypersensitivity reaction to it or any of the fundamental ingredients used in the preparation of the drug. With active meningeal infections, liposomal cytarabine is also contraindicated.

Dosage

Dosage Forms

• Solution, Injection: 10 mg/ml, 20 mg/mL (25 mL), 100 mg/ml
• Intrathecal injection, liposomal: 50 mg/5ml

Administration – Rapid intravenous infusion, infuse over 1 to 3 hours intravenously or subcutaneously or intrathecally.

Storage – Store at room temperature.

Dosing: Adult

1. Acute lymphoblastic leukemia (off-label dosing):

   • Induction regimen, relapsed or refractory- Administer 3,000 mg/sq.meter of cytarabine over 3 hours by intravenous infusion daily for five days in combination with idarubicin for three days.[rx]
   • Dose-intensive regimen- 3,000 mg/sq.meter of cytarabine over 2 hours by intravenous infusion. This dose is to be given every 12 hours on days 2 and 3 (4 doses/cycle) of even-numbered cycles in combination with methotrexate.[rx]
2. Acute myeloid leukemia (remission induction chemotherapy):

   • Administer standard dose 100 mg/sq.meter/day of cytarabine by continuous intravenous infusion for 7 days or give 200 mg/sq.meter/day by continuous intravenous infusion for 7 days(as 100 mg/m2 over 12 hours every 12 hours).[rx]
3. Acute myeloid leukemia consolidation therapy (off-label use):

   • 5+2 regimen: Administer 100 mg/sq.meter/day of cytarabine for five days by intravenous infusion in combination with daunorubicin or idarubicin, or mitoxantrone.[rx][rx]
4. Acute myeloid leukemia salvage treatment (off-label use):

   • CLAG-M regimen: Administer 2,000 mg/sq.meter/day of cytarabine by intravenous infusion over 4 hours for five days in combination with cladribine, G-CSF, and mitoxantrone.[rx]
5. Acute promyelocytic leukemia consolidation therapy (off-label use):

   • First consolidation course: Administer 200 mg/sq.meter/day of cytarabine by intravenous infusion for seven days in combination with daunorubicin.[rx]
   • Second consolidation course:

     • If age is ≤60 years and low risk (WBC <10,000/cubic mm), then administer 1,000 mg/sq.meter of cytarabine every 12 hours for four days (8 doses) by intravenous infusion.
     • If age is <50 years and high risk (WBC ≥10,000/cubic mm), then administer 2,000 mg/sq.meter of cytarabine every 12 hours for five days (10 doses) by intravenous infusion.
     • If age is 50 to 60 years and high risk (WBC ≥10,000/cubic mm), then administer 1500 mg/sq.meter of cytarabine every 12 hours for five days (10 doses) by intravenous infusion.
     • If age is >60 years and high risk (WBC ≥10,000/cubic mm) then administer 1,000 mg/sq.meter every 12 hours for four days (8 doses) by intravenous infusion.
6. Acute promyelocytic leukemia induction (off-label dosing):

   • Administer 200 mg/sq.meter/day of cytarabine by continuous intravenous infusion for seven days, beginning on the third day of treatment in combination with tretinoin and daunorubicin.[rx][rx]

Usual Adult Dose for

Acute Nonlymphocytic Leukemia

Induction as part of combination chemotherapy:

• 100 mg/m2/day by continuous IV infusion (Days 1 through 7) or 100 mg/m2 IV every 12 hours (Days 1 through 7)

Meningeal Leukemia

• The dose ranges from 5 mg/m2 to 75 mg/m2 intrathecally once a day for 4 days to once every 4 days (30 mg/m2 every 4 days until cerebrospinal fluid findings are normal, followed by one additional treatment is the most frequently used dose)

Usual Pediatric Dose for

Acute Nonlymphocytic Leukemia

Induction as part of combination chemotherapy:

• 100 mg/m2/day by continuous IV infusion (Days 1 through 7) or 100 mg/m2 IV every 12 hours (Days 1 through 7)
  

Acute Lymphocytic Leukemia

• The literature and/or local protocol should be consulted.

Meningeal Leukemia

• The dose ranges from 5 mg/m2 to 75 mg/m2 intrathecally once a day for 4 days to once every 4 days (30 mg/m2 every 4 days until cerebrospinal fluid findings are normal, followed by one additional treatment is the most frequently used dose)

Side Effects

The Most Common

• ongoing pain that begins in the stomach area but may spread to the back
• redness, pain, swelling, or burning at the site where the injection was given
• nausea
• vomiting
• diarrhea
• stomach pain
• loss of appetite
• sores in the mouth and throat
• hair loss
• muscle or joint pain
• tiredness
• sore or red eyes

More Common

• pale skin
• fainting
• dizziness
• fast or irregular heartbeat
• rash
• hives
• itching
• difficulty breathing or swallowing
• chest pain
• yellowing of the skin or eyes
• dark-colored urine or decreased urination
• shortness of breath
• sudden change or loss of vision
• seizures
• confusion
• numbness, burning, or tingling in the hands, arms, feet, or legs

Rare

• Headache
• Low blood counts. Your white and red blood cells and platelets may temporarily decrease. This can put you at risk for infection, anemia and/or bleeding. Nadir: White blood cells: 7-10 days, platelets: 12-15 days.
• Nausea and vomiting
• Mouth sores (usually occur 7-10 days after therapy).
• Increases in blood tests measuring liver function. These return to normal once treatment is discontinued. More often associated with high-dose regimens.
• Diarrhea
• Loss of appetite
• Skin rash, redness and itching
• Flu-like symptoms (fever, chills, generalized aches and pains) within the first few days of treatment.
• Pain, redness and skin peeling of the palms of hands and soles of feet (hand-foot syndrome) may occur with high-dose therapy (rare). Use of steroid creams or moisturizers may be helpful.
• Blood test abnormalities: Increase in blood level of uric acid. A medication called allopurinal may be given to decrease these levels.
• Temporary hair loss (uncommon, but thinning may occur).
• Eye pain, tearing, sensitivity to light and blurred vision may occur with high-dose therapy. Often steroid drops or ointment to the eyes are used to prevent or relieve this condition.
• Dizziness, headache, excessive sleepiness, confusion, loss of balance may occur in up to 10% of patients receiving high dose therapy. Onset is usually 5 days after treatment and may last up to 1 week. More often these toxicities are mild and reversible.

Drug interactions

DRUG	INTERACTION
Abatacept	The risk or severity of adverse effects can be increased when Cytarabine is combined with Abatacept.
Abciximab	The risk or severity of bleeding can be increased when Abciximab is combined with Cytarabine.
Acenocoumarol	The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cytarabine.
Acetylsalicylic acid	The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Cytarabine.
Acipimox	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Acipimox.
Acyclovir	The risk or severity of adverse effects can be increased when Acyclovir is combined with Cytarabine.
Adalimumab	The risk or severity of adverse effects can be increased when Adalimumab is combined with Cytarabine.
Adenovirus type 7 vaccine live	The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cytarabine.
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cytarabine.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Cytarabine.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cytarabine.
Alendronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine.
Allogeneic processed thymus tissue	The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Cytarabine.
Allopurinol	The risk or severity of adverse effects can be increased when Allopurinol is combined with Cytarabine.
Alteplase	The risk or severity of bleeding can be increased when Alteplase is combined with Cytarabine.
Altretamine	The risk or severity of adverse effects can be increased when Altretamine is combined with Cytarabine.
Amantadine	The risk or severity of adverse effects can be increased when Amantadine is combined with Cytarabine.
Amiodarone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Amiodarone.
Amphotericin B	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Cytarabine.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Cytarabine.
Anagrelide	The risk or severity of bleeding can be increased when Anagrelide is combined with Cytarabine.
Anakinra	The risk or severity of adverse effects can be increased when Anakinra is combined with Cytarabine.
Ancrod	The risk or severity of bleeding can be increased when Ancrod is combined with Cytarabine.
Anifrolumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Anifrolumab.
Anistreplase	The risk or severity of bleeding can be increased when Anistreplase is combined with Cytarabine.
Anthrax vaccine	The risk or severity of infection can be increased when Anthrax vaccine is combined with Cytarabine.
Antilymphocyte immunoglobulin (horse)	The risk or severity of adverse effects can be increased when Cytarabine is combined with Antilymphocyte immunoglobulin (horse).
Antithrombin Alfa	The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Cytarabine.
Antithrombin III human	The risk or severity of bleeding can be increased when Antithrombin III human is combined with Cytarabine.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Cytarabine.
Apixaban	The risk or severity of bleeding can be increased when Apixaban is combined with Cytarabine.
Apremilast	The risk or severity of adverse effects can be increased when Cytarabine is combined with Apremilast.
Ardeparin	The risk or severity of bleeding can be increased when Ardeparin is combined with Cytarabine.
Argatroban	The risk or severity of bleeding can be increased when Argatroban is combined with Cytarabine.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Arsenic trioxide.
Articaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Articaine.
Atorvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Atorvastatin.
Azacitidine	The risk or severity of adverse effects can be increased when Azacitidine is combined with Cytarabine.
Azathioprine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Azathioprine.
Bacillus calmette-guerin substrain connaught live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Cytarabine.
Bacillus calmette-guerin substrain russian BCG-I live antigen	The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Cytarabine.
Bacillus calmette-guerin substrain tice live antigen	The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Cytarabine.
Baclofen	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Cytarabine.
Baricitinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Baricitinib.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Cytarabine.
BCG vaccine	The risk or severity of infection can be increased when BCG vaccine is combined with Cytarabine.
Beclomethasone dipropionate	The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Cytarabine.
Belatacept	The risk or severity of adverse effects can be increased when Cytarabine is combined with Belatacept.
Belimumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Belimumab.
Belinostat	The risk or severity of adverse effects can be increased when Cytarabine is combined with Belinostat.
Belumosudil	The risk or severity of adverse effects can be increased when Cytarabine is combined with Belumosudil.
Bemiparin	The risk or severity of bleeding can be increased when Bemiparin is combined with Cytarabine.
Bendamustine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Bendamustine.
Bendroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Cytarabine.
Benzocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Benzocaine.
Benzthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Cytarabine.
Benzyl alcohol	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Benzyl alcohol.
Betamethasone	The risk or severity of adverse effects can be increased when Betamethasone is combined with Cytarabine.
Betrixaban	The risk or severity of bleeding can be increased when Betrixaban is combined with Cytarabine.
Bexarotene	The risk or severity of adverse effects can be increased when Bexarotene is combined with Cytarabine.
Bezafibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Bezafibrate.
Bimekizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Bimekizumab.
Bivalirudin	The risk or severity of bleeding can be increased when Bivalirudin is combined with Cytarabine.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Cytarabine.
Blinatumomab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Blinatumomab.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Cytarabine.
Bosutinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Bosutinib.
Brentuximab vedotin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Brentuximab vedotin.
Brodalumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Brodalumab.
Budesonide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Budesonide.
Bumetanide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Bumetanide is combined with Cytarabine.
Bupivacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Bupivacaine.
Busulfan	The risk or severity of adverse effects can be increased when Cytarabine is combined with Busulfan.
Butacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Butacaine.
Butamben	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Butamben.
Cabazitaxel	The risk or severity of adverse effects can be increased when Cytarabine is combined with Cabazitaxel.
Canakinumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Canakinumab.
Cangrelor	The risk or severity of bleeding can be increased when Cangrelor is combined with Cytarabine.
Capecitabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Capecitabine.
Caplacizumab	The risk or severity of bleeding can be increased when Caplacizumab is combined with Cytarabine.
Capsaicin	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Capsaicin.
Captopril	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Captopril.
Carbamazepine	The risk or severity of adverse effects can be increased when Carbamazepine is combined with Cytarabine.
Carbimazole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Cytarabine.
Carboplatin	The risk or severity of adverse effects can be increased when Carboplatin is combined with Cytarabine.
Carfilzomib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Carfilzomib.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Cytarabine.
Cedazuridine	The serum concentration of Cytarabine can be increased when it is combined with Cedazuridine.
Cerivastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Cytarabine.
Certolizumab pegol	The risk or severity of adverse effects can be increased when Cytarabine is combined with Certolizumab pegol.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cytarabine.
Chloramphenicol	The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cytarabine.
Chloroprocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Chloroprocaine.
Chloroquine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Cytarabine.
Chlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Chlorothiazide is combined with Cytarabine.
Chlorpheniramine	The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Cytarabine.
Choline	The risk or severity of adverse effects can be increased when Choline is combined with Cytarabine.
Choline salicylate	The risk or severity of adverse effects can be increased when Choline salicylate is combined with Cytarabine.
Ciclesonide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ciclesonide.
Cilostazol	The risk or severity of bleeding can be increased when Cilostazol is combined with Cytarabine.

Cimetidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Cytarabine.
Cinchocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Cinchocaine.
Ciprofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ciprofibrate.
Ciprofloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Cytarabine.
Cisplatin	The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine.
Cladribine	The risk or severity of adverse effects can be increased when Cladribine is combined with Cytarabine.
Clobetasol propionate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Clobetasol propionate.
Clofarabine	The risk or severity of adverse effects can be increased when Clofarabine is combined with Cytarabine.
Clofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Clofibrate is combined with Cytarabine.
Clopidogrel	The risk or severity of adverse effects can be increased when Clopidogrel is combined with Cytarabine.
Clozapine	The risk or severity of neutropenia can be increased when Cytarabine is combined with Clozapine.
Cocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Cocaine.
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Cytarabine.
Colchicine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Colchicine.
Corticotropin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Corticotropin.
Cortisone acetate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Cortisone acetate.
Cyanocobalamin	The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cytarabine.
Cyclopenthiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Cytarabine.
Cyclophosphamide	The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Cytarabine.
Cyclosporine	Cytarabine may increase the immunosuppressive activities of Cyclosporine.
Cyclothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Cytarabine.
Dabigatran	The risk or severity of bleeding can be increased when Dabigatran is combined with Cytarabine.
Dabigatran etexilate	The risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Cytarabine.
Dacarbazine	The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cytarabine.
Dacomitinib	The risk or severity of adverse effects can be increased when Dacomitinib is combined with Cytarabine.
Dactinomycin	The risk or severity of adverse effects can be increased when Dactinomycin is combined with Cytarabine.
Dalteparin	The risk or severity of bleeding can be increased when Dalteparin is combined with Cytarabine.
Danaparoid	The risk or severity of bleeding can be increased when Danaparoid is combined with Cytarabine.
Daptomycin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Cytarabine.
Darbepoetin alfa	The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cytarabine.
Dasatinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Dasatinib.
Decitabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Decitabine.
Defibrotide	The risk or severity of bleeding can be increased when Defibrotide is combined with Cytarabine.
Deflazacort	The risk or severity of adverse effects can be increased when Cytarabine is combined with Deflazacort.
Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.
Desipramine	The risk or severity of adverse effects can be increased when Desipramine is combined with Cytarabine.
Desirudin	The risk or severity of bleeding can be increased when Desirudin is combined with Cytarabine.
Desoximetasone	The risk or severity of adverse effects can be increased when Desoximetasone is combined with Cytarabine.
Deucravacitinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Deucravacitinib.
Dexamethasone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Dexamethasone.
Dexchlorpheniramine maleate	The risk or severity of adverse effects can be increased when Dexchlorpheniramine maleate is combined with Cytarabine.
Dexrazoxane	The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cytarabine.
Dextran	The risk or severity of bleeding can be increased when Dextran is combined with Cytarabine.
Dicoumarol	The risk or severity of bleeding can be increased when Dicoumarol is combined with Cytarabine.
Difluocortolone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Difluocortolone.
Dimethyl fumarate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Dimethyl fumarate.
Dinoprostone	The risk or severity of adverse effects can be increased when Dinoprostone is combined with Cytarabine.
Dinutuximab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Dinutuximab.
Diphenhydramine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Diphenhydramine.
Dipyridamole	The risk or severity of bleeding can be increased when Dipyridamole is combined with Cytarabine.
Diroximel fumarate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Diroximel fumarate.
Disopyramide	The risk or severity of adverse effects can be increased when Disopyramide is combined with Cytarabine.
Docetaxel	The risk or severity of adverse effects can be increased when Cytarabine is combined with Docetaxel.
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Cytarabine.
Doxorubicin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Doxorubicin.
Dronedarone	The risk or severity of adverse effects can be increased when Dronedarone is combined with Cytarabine.
Drotrecogin alfa	The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cytarabine.
Dyclonine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Dyclonine.
Eculizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Eculizumab.
Edetic acid	The risk or severity of bleeding can be increased when Edetic acid is combined with Cytarabine.
Edoxaban	The risk or severity of bleeding can be increased when Edoxaban is combined with Cytarabine.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Cytarabine.
Efavirenz	The risk or severity of adverse effects can be increased when Efavirenz is combined with Cytarabine.
Emapalumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Emapalumab.
Enalapril	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Cytarabine.
Enoxaparin	The risk or severity of bleeding can be increased when Enoxaparin is combined with Cytarabine.
Epirubicin	The risk or severity of adverse effects can be increased when Epirubicin is combined with Cytarabine.
Epoprostenol	The risk or severity of bleeding can be increased when Epoprostenol is combined with Cytarabine.
Eprosartan	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Cytarabine.
Eptifibatide	The risk or severity of bleeding can be increased when Eptifibatide is combined with Cytarabine.
Eribulin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Eribulin.
Erythropoietin	The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cytarabine.
Estradiol acetate	The risk or severity of adverse effects can be increased when Estradiol acetate is combined with Cytarabine.
Estradiol benzoate	The risk or severity of adverse effects can be increased when Estradiol benzoate is combined with Cytarabine.
Estradiol cypionate	The risk or severity of adverse effects can be increased when Estradiol cypionate is combined with Cytarabine.
Estradiol dienanthate	The risk or severity of adverse effects can be increased when Estradiol dienanthate is combined with Cytarabine.
Estradiol valerate	The risk or severity of adverse effects can be increased when Estradiol valerate is combined with Cytarabine.
Estramustine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Estramustine.
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Cytarabine.
Ethanol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ethanol is combined with Cytarabine.
Ethyl chloride	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Ethyl chloride.
Etidocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Etidocaine.
Etoposide	The risk or severity of adverse effects can be increased when Etoposide is combined with Cytarabine.
Everolimus	The risk or severity of adverse effects can be increased when Cytarabine is combined with Everolimus.
Fenofibrate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fenofibrate.
Fenofibric acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fenofibric acid.
Filgotinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Filgotinib.
Fingolimod	Cytarabine may increase the immunosuppressive activities of Fingolimod.
Floxuridine	The risk or severity of adverse effects can be increased when Floxuridine is combined with Cytarabine.
Flucytosine	The therapeutic efficacy of Flucytosine can be decreased when used in combination with Cytarabine.
Fludarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Fludarabine.
Fludrocortisone	The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Cytarabine.
Fluindione	The risk or severity of bleeding can be increased when Fluindione is combined with Cytarabine.
Flunisolide	The risk or severity of adverse effects can be increased when Flunisolide is combined with Cytarabine.
Fluocinolone acetonide	The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Cytarabine.
Fluocinonide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocinonide.
Fluocortolone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluocortolone.
Fluorometholone	The risk or severity of adverse effects can be increased when Fluorometholone is combined with Cytarabine.
Fluorouracil	The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine.
Flupentixol	The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cytarabine.

Fluticasone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluticasone.
Fluticasone furoate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Fluticasone furoate.
Fluticasone propionate	The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Cytarabine.
Fluvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fluvastatin.
Fondaparinux	The risk or severity of bleeding can be increased when Fondaparinux is combined with Cytarabine.
Formoterol	The risk or severity of adverse effects can be increased when Formoterol is combined with Cytarabine.
Fusidic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Fusidic acid.
Gallium nitrate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Gallium nitrate.
Ganciclovir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ganciclovir.
Gemcitabine	The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cytarabine.
Gemfibrozil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Gemfibrozil.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cytarabine.
Gilteritinib	The risk or severity of adverse effects can be increased when Gilteritinib is combined with Cytarabine.
Glatiramer	The risk or severity of adverse effects can be increased when Cytarabine is combined with Glatiramer.
Golimumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Golimumab.
Guanfacine	The risk or severity of adverse effects can be increased when Guanfacine is combined with Cytarabine.
Guanidine	The risk or severity of adverse effects can be increased when Guanidine is combined with Cytarabine.
Guselkumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Guselkumab.
Heparin	The risk or severity of bleeding can be increased when Heparin is combined with Cytarabine.
Human adenovirus e serotype 4 strain cl-68578 antigen	The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cytarabine.
Hydrochlorothiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydrochlorothiazide is combined with Cytarabine.
Hydrocortisone acetate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone acetate.
Hydrocortisone butyrate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone butyrate.
Hydrocortisone succinate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydrocortisone succinate.
Hydroflumethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Hydroflumethiazide is combined with Cytarabine.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxychloroquine.
Hydroxyurea	The risk or severity of adverse effects can be increased when Cytarabine is combined with Hydroxyurea.
Ibandronate	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ibandronate is combined with Cytarabine.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cytarabine.
Ibrutinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ibrutinib.
Icosapent ethyl	The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cytarabine.
Idarubicin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Idarubicin.
Idelalisib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Idelalisib.
Ifosfamide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ifosfamide.
Iloprost	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Iloprost.
Imatinib	The risk or severity of adverse effects can be increased when Imatinib is combined with Cytarabine.
Indinavir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Cytarabine.
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Cytarabine.
Inebilizumab	The risk or severity of infection can be increased when Cytarabine is combined with Inebilizumab.
Infliximab	The risk or severity of adverse effects can be increased when Infliximab is combined with Cytarabine.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Cytarabine.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Cytarabine.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Cytarabine.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Cytarabine.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Cytarabine.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Cytarabine.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Cytarabine.
Ipecac	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ipecac.
Irinotecan	The risk or severity of adverse effects can be increased when Irinotecan is combined with Cytarabine.
Isoniazid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isoniazid is combined with Cytarabine.
Isotretinoin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Isotretinoin is combined with Cytarabine.
Ivermectin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Cytarabine.
Ixabepilone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixabepilone.
Ixekizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ixekizumab.
Lamivudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lamivudine is combined with Cytarabine.
Leflunomide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Leflunomide.
Lenalidomide	The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cytarabine.
Lepirudin	The risk or severity of bleeding can be increased when Lepirudin is combined with Cytarabine.
Lercanidipine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Cytarabine.
Letrozole	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Letrozole.
Leuprolide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Cytarabine.
Levobupivacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Levobupivacaine.
Lidocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Lidocaine.
Linagliptin	The risk or severity of adverse effects can be increased when Linagliptin is combined with Cytarabine.
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Cytarabine.
Lipegfilgrastim	Cytarabine may increase the myelosuppressive activities of Lipegfilgrastim.
Lomustine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Lomustine.
Lopinavir	The serum concentration of Cytarabine can be increased when it is combined with Lopinavir.
Lovastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Cytarabine.
Magnesium	The serum concentration of Magnesium can be decreased when it is combined with Cytarabine.
Mebeverine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Mebeverine.
Mechlorethamine	The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Cytarabine.
Mefloquine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Cytarabine.
Meloxicam	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Meloxicam.
Melphalan	The risk or severity of adverse effects can be increased when Cytarabine is combined with Melphalan.
Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine	The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Cytarabine.
Mepivacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Mepivacaine.
Mepolizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Mepolizumab.
Meprednisone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Meprednisone.
Mercaptopurine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Mercaptopurine.
Methimazole	The risk or severity of adverse effects can be increased when Methimazole is combined with Cytarabine.
Methotrexate	The risk or severity of adverse effects can be increased when Methotrexate is combined with Cytarabine.
Methoxy polyethylene glycol-epoetin beta	The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cytarabine.
Methyldopa	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methyldopa is combined with Cytarabine.
Methylprednisolone	The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cytarabine.
Metoclopramide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Metoclopramide.
Minocycline	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Minocycline.
Mitomycin	The risk or severity of adverse effects can be increased when Mitomycin is combined with Cytarabine.
Mitoxantrone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Mitoxantrone.
Mometasone furoate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Mometasone furoate.
Monomethyl fumarate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Monomethyl fumarate.
Montelukast	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Cytarabine.
Mosunetuzumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Mosunetuzumab.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Cytarabine.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Cytarabine.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Cytarabine is combined with Mycophenolic acid.
Nadroparin	The risk or severity of bleeding can be increased when Nadroparin is combined with Cytarabine.
Nafarelin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Cytarabine.
Naltrexone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Naltrexone is combined with Cytarabine.

Natalizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.
Nelarabine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Nelarabine.
Nelfinavir	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cytarabine.
Nevirapine	The risk or severity of adverse effects can be increased when Nevirapine is combined with Cytarabine.
Niacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Cytarabine.
Nicotine	The risk or severity of adverse effects can be increased when Nicotine is combined with Cytarabine.
Nilotinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Nilotinib.
Nimesulide	The risk or severity of bleeding can be increased when Nimesulide is combined with Cytarabine.
Nizatidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Cytarabine.
Norfloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Norfloxacin.
Obinutuzumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Obinutuzumab.
Ocrelizumab	Ocrelizumab may increase the immunosuppressive activities of Cytarabine.
Ofatumumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ofatumumab.
Ofloxacin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ofloxacin.
Olaparib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Olaparib.
Oxaliplatin	The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Cytarabine.
Oxetacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Oxetacaine.
Oxybuprocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Oxybuprocaine.
Ozanimod	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ozanimod.
Paclitaxel	The risk or severity of adverse effects can be increased when Cytarabine is combined with Paclitaxel.
Pacritinib	The serum concentration of Cytarabine can be increased when it is combined with Pacritinib.
Palbociclib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Palbociclib.
Palifermin	The therapeutic efficacy of Palifermin can be decreased when used in combination with Cytarabine.
Pamidronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Cytarabine.
Pancuronium	The risk or severity of adverse effects can be increased when Pancuronium is combined with Cytarabine.
Panobinostat	The risk or severity of adverse effects can be increased when Cytarabine is combined with Panobinostat.
Parnaparin	The risk or severity of bleeding can be increased when Parnaparin is combined with Cytarabine.
Pazopanib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Pazopanib.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Cytarabine.
Pegcetacoplan	The risk or severity of adverse effects can be increased when Cytarabine is combined with Pegcetacoplan.
Peginesatide	The risk or severity of Thrombosis can be increased when Peginesatide is combined with Cytarabine.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Cytarabine.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Cytarabine.
Peginterferon beta-1a	The risk or severity of adverse effects can be increased when Cytarabine is combined with Peginterferon beta-1a.
Pemetrexed	The risk or severity of adverse effects can be increased when Pemetrexed is combined with Cytarabine.
Penicillamine	The risk or severity of adverse effects can be increased when Penicillamine is combined with Cytarabine.
Pentosan polysulfate	The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Cytarabine.
Pentostatin	The risk or severity of adverse effects can be increased when Pentostatin is combined with Cytarabine.
Pentoxifylline	The risk or severity of bleeding can be increased when Pentoxifylline is combined with Cytarabine.
Phenformin	The risk or severity of adverse effects can be increased when Phenformin is combined with Cytarabine.
Phenindione	The risk or severity of bleeding can be increased when Phenindione is combined with Cytarabine.
Phenol	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Phenol.
Phenoxybenzamine	The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Cytarabine.
Phenprocoumon	The risk or severity of bleeding can be increased when Phenprocoumon is combined with Cytarabine.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Cytarabine.
Phenytoin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Cytarabine.
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cytarabine.
Pirfenidone	The risk or severity of adverse effects can be increased when Cytarabine is combined with Pirfenidone.
Pitavastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Pitavastatin.
Pitolisant	The risk or severity of adverse effects can be increased when Pitolisant is combined with Cytarabine.
Polythiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Cytarabine.
Pomalidomide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Pomalidomide.
Ponatinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponatinib.
Ponesimod	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ponesimod.
Pralatrexate	The risk or severity of adverse effects can be increased when Cytarabine is combined with Pralatrexate.
Pramocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Pramocaine.
Prasugrel	The risk or severity of bleeding can be increased when Prasugrel is combined with Cytarabine.
Pravastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Cytarabine.
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Cytarabine.
Prednisolone	The risk or severity of adverse effects can be increased when Prednisolone is combined with Cytarabine.
Prednisone	The risk or severity of adverse effects can be increased when Prednisone is combined with Cytarabine.
Prilocaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Prilocaine.
Probenecid	The risk or severity of adverse effects can be increased when Probenecid is combined with Cytarabine.
Procainamide	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Procainamide.
Procaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Procaine.
Procarbazine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Procarbazine.
Progesterone	The risk or severity of adverse effects can be increased when Progesterone is combined with Cytarabine.
Proparacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Proparacaine.
Propofol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propofol is combined with Cytarabine.
Propoxycaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Propoxycaine.
Propylthiouracil	The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Cytarabine.
Protein C	The risk or severity of bleeding can be increased when Protein C is combined with Cytarabine.
Protein S human	The risk or severity of bleeding can be increased when Protein S human is combined with Cytarabine.
Quinidine	The risk or severity of adverse effects can be increased when Quinidine is combined with Cytarabine.
Quinine	The risk or severity of adverse effects can be increased when Quinine is combined with Cytarabine.
Raltegravir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Raltegravir.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Cytarabine.
Ranitidine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ranitidine is combined with Cytarabine.
Ravulizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ravulizumab.
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Cytarabine.
Reteplase	The risk or severity of bleeding can be increased when Reteplase is combined with Cytarabine.
Reviparin	The risk or severity of bleeding can be increased when Reviparin is combined with Cytarabine.
Rilonacept	The risk or severity of adverse effects can be increased when Cytarabine is combined with Rilonacept.
Risankizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Risankizumab.
Risedronic acid	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Risedronic acid is combined with Cytarabine.
Ritonavir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Cytarabine.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Cytarabine.
Rivaroxaban	The risk or severity of bleeding can be increased when Rivaroxaban is combined with Cytarabine.
Rocuronium	The risk or severity of adverse effects can be increased when Rocuronium is combined with Cytarabine.
Roflumilast	Roflumilast may increase the immunosuppressive activities of Cytarabine.
Ropeginterferon alfa-2b	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ropeginterferon alfa-2b.
Ropivacaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Ropivacaine.
Rosuvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Rosuvastatin.
Rubella virus vaccine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cytarabine.
Ruxolitinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Ruxolitinib.
Salmeterol	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Salmeterol is combined with Cytarabine.
Saquinavir	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Saquinavir.
Sarilumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Sarilumab.
Satralizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Satralizumab.
Secukinumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Secukinumab.

Sildenafil	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Cytarabine.
Siltuximab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Siltuximab.
Simvastatin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Simvastatin is combined with Cytarabine.
Siponimod	The risk or severity of adverse effects can be increased when Cytarabine is combined with Siponimod.
Sipuleucel-T	The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cytarabine.
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Cytarabine.
Sodium citrate	The risk or severity of bleeding can be increased when Sodium citrate is combined with Cytarabine.
Somatotropin	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Cytarabine.
Sorafenib	The risk or severity of adverse effects can be increased when Sorafenib is combined with Cytarabine.
Spesolimab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Spesolimab.
Stavudine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Cytarabine.
Streptokinase	The risk or severity of bleeding can be increased when Streptokinase is combined with Cytarabine.
Streptozocin	The risk or severity of adverse effects can be increased when Streptozocin is combined with Cytarabine.
Sulfamethoxazole	The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cytarabine.
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Cytarabine.
Sulfinpyrazone	The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Cytarabine.
Sulodexide	The risk or severity of bleeding can be increased when Sulodexide is combined with Cytarabine.
Sunitinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Sunitinib.
Tacrine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Cytarabine.
Tacrolimus	Tacrolimus may increase the immunosuppressive activities of Cytarabine.
Tedizolid phosphate	The risk or severity of myelosuppression can be increased when Cytarabine is combined with Tedizolid phosphate.
Temozolomide	The risk or severity of adverse effects can be increased when Temozolomide is combined with Cytarabine.
Temsirolimus	The risk or severity of adverse effects can be increased when Cytarabine is combined with Temsirolimus.
Tenecteplase	The risk or severity of bleeding can be increased when Tenecteplase is combined with Cytarabine.
Teniposide	The risk or severity of adverse effects can be increased when Teniposide is combined with Cytarabine.
Teprotumumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Teprotumumab.
Terbinafine	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Terbinafine is combined with Cytarabine.
Teriflunomide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Teriflunomide.
Tetracaine	The risk or severity of methemoglobinemia can be increased when Cytarabine is combined with Tetracaine.
Thalidomide	The risk or severity of adverse effects can be increased when Cytarabine is combined with Thalidomide.
Thiotepa	The risk or severity of adverse effects can be increased when Cytarabine is combined with Thiotepa.
Ticagrelor	The risk or severity of bleeding can be increased when Ticagrelor is combined with Cytarabine.
Ticlopidine	The risk or severity of bleeding can be increased when Ticlopidine is combined with Cytarabine.
Tinzaparin	The risk or severity of bleeding can be increased when Tinzaparin is combined with Cytarabine.
Tioguanine	The risk or severity of adverse effects can be increased when Tioguanine is combined with Cytarabine.
Tirofiban	The risk or severity of bleeding can be increased when Tirofiban is combined with Cytarabine.
Tixocortol	The risk or severity of adverse effects can be increased when Cytarabine is combined with Tixocortol.
Tocilizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Tocilizumab.
Tofacitinib	Cytarabine may increase the immunosuppressive activities of Tofacitinib.
Topotecan	The risk or severity of adverse effects can be increased when Cytarabine is combined with Topotecan.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Cytarabine.
Trabectedin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Trabectedin.
Trastuzumab	Trastuzumab may increase the neutropenic activities of Cytarabine.
Trastuzumab emtansine	The risk or severity of adverse effects can be increased when Cytarabine is combined with Trastuzumab emtansine.
Tretinoin	The risk or severity of adverse effects can be increased when Tretinoin is combined with Cytarabine.
Triamcinolone	The risk or severity of adverse effects can be increased when Triamcinolone is combined with Cytarabine.
Triazolam	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triazolam is combined with Cytarabine.
Trichlormethiazide	The risk or severity of neutropenia and thrombocytopenia can be increased when Trichlormethiazide is combined with Cytarabine.
Trifluridine	The risk or severity of adverse effects can be increased when Trifluridine is combined with Cytarabine.
Triflusal	The risk or severity of bleeding can be increased when Triflusal is combined with Cytarabine.
Trilostane	The risk or severity of adverse effects can be increased when Cytarabine is combined with Trilostane.
Trimethoprim	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Cytarabine.
Typhoid Vaccine Live	The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cytarabine.
Ubidecarenone	The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cytarabine is combined with Ubidecarenone.
Upadacitinib	The risk or severity of adverse effects can be increased when Cytarabine is combined with Upadacitinib.
Urokinase	The risk or severity of bleeding can be increased when Urokinase is combined with Cytarabine.
Varicella zoster vaccine (live/attenuated)	The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cytarabine.
Vedolizumab	The risk or severity of adverse effects can be increased when Cytarabine is combined with Vedolizumab.
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Cytarabine.
Vibrio cholerae CVD 103-HgR strain live antigen	The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cytarabine.
Vilanterol	The risk or severity of adverse effects can be increased when Cytarabine is combined with Vilanterol.
Vinblastine	The risk or severity of adverse effects can be increased when Vinblastine is combined with Cytarabine.
Vincristine	The risk or severity of adverse effects can be increased when Vincristine is combined with Cytarabine.
Vindesine	The risk or severity of adverse effects can be increased when Vindesine is combined with Cytarabine.
Vinorelbine	The risk or severity of adverse effects can be increased when Vinorelbine is combined with Cytarabine.
Voclosporin	The risk or severity of adverse effects can be increased when Cytarabine is combined with Voclosporin.
Vorapaxar	The risk or severity of bleeding can be increased when Vorapaxar is combined with Cytarabine.
Vorinostat	The risk or severity of adverse effects can be increased when Cytarabine is combined with Vorinostat.
Warfarin	The risk or severity of bleeding can be increased when Warfarin is combined with Cytarabine.
Ximelagatran	The risk or severity of bleeding can be increased when Ximelagatran is combined with Cytarabine.
Yellow fever vaccine	The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cytarabine.
Zidovudine	The risk or severity of adverse effects can be increased when Zidovudine is combined with Cytarabine.

Pregnancy and Lactation

When To Contact Your Doctor or Health Care Provider:

Contact your health care provider immediately, day or night, if you should experience any of the following symptoms:

• Fever of 100.4°F (38°C) or higher or chills (possible signs of infection).
• Chest pain or heart palpitations
• Inability to pass urine

The following symptoms require medical attention, but are not an emergency. Contact your health care provider within 24 hours of noticing any of the following:

• Diarrhea (4-6 episodes in a 24 hour period)
• Nausea (unable to drink fluids and unrelieved with prescription medication).
• Vomiting (more than 4-5 times in a 24 hour period)
• Unusual bleeding or bruising
• Black or tarry stools, or blood in your stools or urine
• Extreme fatigue (unable to carry on self-care activities)
• Mouth sores (painful redness, swelling or ulcers)
• Cough and/or shortness of breath
• Excessive sleepiness or confusion
• Changes in balance and coordination
• Yellowing of the skin or eyes
• Changes in vision or burning/or tearing of eyes
• Swelling, redness and pain in one leg or arm and not the other
• Stomach pains

Always inform your health care provider if you experience any unusual symptoms.

Precautions:

• Before starting cytarabine treatment, make sure you tell your doctor about any other medications you are taking (including prescription, over-the-counter, vitamins, herbal remedies, etc.). Do not take aspirin, products containing aspirin unless your doctor specifically permits this.
• Do not receive any kind of immunization or vaccination without your doctor’s approval while taking cytarabine.
• Inform your health care professional if you are pregnant or may be pregnant prior to starting this treatment. Pregnancy category D (cytarabine may be hazardous to the fetus. Women who are pregnant or become pregnant must be advised of the potential hazard to the fetus).
• For both men and women: Use contraceptives, and do not conceive a child (get pregnant) while taking cytarabine. Barrier methods of contraception, such as condoms, are recommended.

Self-Care Tips:

• Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise.
• You may be at risk of infection so try to avoid crowds or people with colds, and report fever or any other signs of infection immediately to your health care provider.
• Wash your hands often.
• To help treat/prevent mouth sores, use a soft toothbrush, and rinse three times a day with 1/2 to 1 teaspoon of baking soda and/or 1/2 to 1 teaspoon of salt mixed with 8 ounces of water.
• Use an electric razor and a soft toothbrush to minimize bleeding.
• Avoid contact sports or activities that could cause injury.
• To reduce nausea, take anti-nausea medications as prescribed by your doctor, and eat small, frequent meals.
• Keeps palms of hands and soles of feet moist using emollients such as Aveeno®, Udder Cream, Lubriderm® or Bag Balm®.
• Avoid sun exposure. Wear SPF 30 (or higher) sunblock and protective clothing.
• In general, drinking alcoholic beverages should be kept to a minimum or avoided completely. You should discuss this with your doctor.
• Get plenty of rest.
• Maintain good nutrition.
• If you experience symptoms or side effects, be sure to discuss them with your health care team. They can prescribe medications and/or offer other suggestions that are effective in managing such problems.

References

Show More